Send us a text

In a monumental moment for combatting Fatty Liver disease, NICE has published the much anticipated evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. Such a positive announcement comes at no better time than the start of the Surfing NASH ongoing coverage of International #NASHDay 2023 . To kick off the occasion, this first episode features hepatology researcher and KOL, William Alazawi, and new guest Vanessa Hebditch who serves as Director of Communications and Policy at the British Liver Trust. The panelists, alongside Louise Campbell and Roger Green, celebrate and comment on the new guidance on FibroScan use in the UK.

In this session, each panelist offers their own take on where the devil is in the details can be applied to this subject. be themed. Much of the discussion comprises a fascinating interplay of ideas between Will and Louise about the best ways to implement community screening and more broadly, chronic disease management within the NHS system. Listen on to find out more.

If you have questions or interest around NICE and FibroScan use, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

Stay Safe and Surf On!